Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

Latest Data & Signals Issued

Signal Type Signal Value Data
Score -1.892 19 days ( -2.99 % )
Last Price $1.72 8.86 %
High/ Low $1.58 - $1.72 20.88%
Chg 7 Days 15.44 % $1.49 $1.72
Chg 30 Days -8.99 % $1.89 $1.72
Chg 12 mos -1.71 % $1.75 $1.72
Trend - 3 mos 1.69 % Width: 113.40 %
Trend - 12 mos -6.25 % Width: 161.89 %
Pred. range - 3 mos $1.20 - $2.55 -30.51 % - 48.29 %
Pred. range - 12 mos $0.89 - $2.32 -48.54 % - 34.76 %
Short MA avg 3 mos Buy Apr 30, 2024 - 8 days
Long MA avg 3 mos Sell Apr 12, 2024 - 20 days
Short/Long MA avg 3 mos Sell Apr 16, 2024 - 18 days
Short MA avg 12 mos Buy May 03, 2024 - 5 days
Long MA avg 12 mos Buy May 01, 2024 - 7 days
Short/Long MA avg 12 mos Buy Feb 08, 2024 - 64 days
Pivot Short Buy Apr 02, 2024 - 28 days
Bollinger Buy Feb 06, 2024 - 66 days
MACD Buy No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!

About NextCure Inc.

NextCure. NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune sup... NXTC Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT